

TABLE OF CONTENTS

LIST OF ABBREVIATIONS	I
SUMMARY	II
ZUSAMMENFASSUNG	IV
1. Introduction	1
1.1. The equine malignant melanoma	1
1.1.1. Tumor classification	2
1.1.2. Etiology.....	2
1.1.3. Gross pathology and diagnosis	3
1.1.4. Clinical signs in diseased horses.....	3
1.1.5. Current treatment options	4
1.2. The equine sarcoid: an overview.....	5
1.3. Topical drug application	5
1.3.1. Why the topical (epicutaneous) approach to treat equine skin cancer?.....	5
1.3.2. Drug transport across the skin	6
1.4. Naturally occurring substances in plane bark and their synthetically modified derivatives	7
1.4.1. Betulinic acid.....	8
1.4.2. Betulinic acid derivative NVX-207.....	9
1.4.3. Betulin derivative betulinyl-bis-sulfamate	9
1.5. Hypotheses and aims of the thesis	10
2. Manuscript I: Betulinic acid shows anticancer activity against equine melanoma cells and permeates isolated equine skin <i>in vitro</i>	13
2.1. Supplemental data	23
3. Manuscript II: <i>In vitro</i> assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer	25

4. Manuscript III: Concentration profiles and safety of topically applied betulinic acid and NVX-207 in eight healthy horses – A randomized, blinded, placebo-controlled, crossover pilot study.....	49
5. Manuscript IV: Effects of topically applied betulinic acid and NVX-207 on early stage equine melanoma – A prospective, randomized, double-blind, placebo-controlled pilot study.....	63
6. General discussion	85
6.1. Summarized findings	85
6.2. Interpretation of the findings.....	85
6.2.1. <i>In vitro</i> cell culture experiments	86
6.2.2. <i>In vitro</i> permeation studies	89
6.2.3. <i>In vivo</i> safety and permeation studies	91
6.2.4. <i>In vivo</i> efficacy study.....	94
7. Major findings and conclusions.....	101
8. Future perspectives.....	103
9. References.....	105
Affidavit.....	117
Acknowledgements.....	119